12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CPX-351: Phase III started

On Dec. 26, 2012, Celator said it began an open-label, North American Phase III trial to compare 100 units/m 2 IV CPX-351 on days 1, 3 and 5 vs. 100...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >